08:00 , Dec 11, 2014 |  BC Innovations  |  Cover Story

Universal reversal for heparin

Titrating heparin treatment is a balancing act for hematologists trying to control blood coagulation without causing excessive bleeding. A synthetic heparin reversal agent from The University of British Columbia uses a dendritic polymer to neutralize...
07:00 , Sep 29, 2014 |  BioCentury  |  Regulation

Patient factors

A dearth of options for patients who develop neutralizing antibodies against recombinant blood clotting factor therapies for bleeding disorders was one of the major concerns expressed by patient advocates last week at FDA's patient-focused drug...
08:00 , Feb 27, 2014 |  BC Innovations  |  Targets & Mechanisms

The XII factor

Factor XII sits atop one branch of the clotting cascade but has not been pursued for treating and preventing thrombosis because it was seen as a minor player in blood coagulation. Now, a group from...
08:00 , Nov 7, 2011 |  BC Week In Review  |  Company News

Afexa, Valeant Pharmaceuticals deal

Valeant completed its tender offer for Afexa, and now holds 89.5 million shares, or 81.6% of Afexa's outstanding shares. Valeant said it would acquire the remaining Afexa shares in a subsequent acquisition transaction. Last month,...
07:00 , Oct 24, 2011 |  BC Week In Review  |  Company News

Afexa board of directors update

Afexa Life Sciences Inc. (TSX:FXA), Edmonton, Alberta   Business: Nutraceuticals   Appointed: Robert Chai-Onn as chairman, while remaining EVP, general counsel and corporate secretary of Valeant Pharmaceuticals International Inc.   ...
07:00 , Oct 24, 2011 |  BC Week In Review  |  Company News

Afexa, Valeant Pharmaceuticals deal

Valeant extended its tender offer to acquire Afexa for C$0.85 per share, or about C$87.7 million ($87.2 million), to Oct. 27. At Oct. 17, 80.9 million shares, or about 73.8% of outstanding shares, had been...
07:00 , Oct 24, 2011 |  BC Week In Review  |  Company News

Afexa management update

Afexa Life Sciences Inc. (TSX:FXA), Edmonton, Alberta   Business: Nutraceuticals   Hired: Thomas Schlader as president and CEO, while remaining president of Valeant Pharmaceuticals International Inc.'s Valeant Canada Ltd. subsidiary   ...
07:00 , Oct 10, 2011 |  BC Week In Review  |  Company News

Afexa, Paladin, Valeant Pharmaceuticals deal

Paladin said last week that no Afexa shares would be taken up when its offer expired at 8 p.m. EDT on Oct. 7 because a basic condition of its unsolicited tender offer to acquire Afexa...
07:00 , Oct 3, 2011 |  BC Week In Review  |  Company News

Afexa, Paladin, Valeant Pharmaceuticals deal

Valeant increased its tender offer to acquire Afexa to C$0.85 per share in cash after Paladin increased its unsolicited tender offer to acquire Afexa to C$0.81 per share in cash earlier in the week. Valeant's...
07:00 , Sep 19, 2011 |  BC Week In Review  |  Company News

Afexa, Paladin, Valeant Pharmaceuticals deal

Valeant began its tender offer to acquire Afexa for C$0.71 per share in cash, or about C$76 million ($75.9 million). The offer expires at 5 p.m. MST on Oct. 17. Separately last week, Paladin extended...